
Xpylon News Medical
Get insights into the most recent breakthroughs, regulations, and trends in the medical field. Xpylon News Medical covers everything from pharmaceuticals to healthcare technology.
Roanoke Seeks $5M State Funding for Biotech Clean Rooms ๐งช

Roanoke officials are pushing for $5 million in state funding to build clean rooms in a new biotech incubator on South Jefferson Street. The site, a former Carilion Clinic building, is undergoing renovations to house shared lab space, expected to open by late 2025.
Governor Glenn Youngkin and the Virginia House of Delegates included the funding in their budget proposals, but the Senate removed it. Local leaders, including Roanoke Economic Development Director Marc Nelson, continue to advocate for its approval.
Clean rooms are vital for biotech manufacturing, especially for cell and gene therapy companies, a sector Roanoke hopes to attract. The city must secure an anchor tenant and match the funding to move forward. Meanwhile, a smaller modular clean room at Fralin Biomedical Research Institute, funded by GO Virginia and private investment, is set to open in March.
The final decision on state funding is expected by February 22 as lawmakers finalize the budget.
Orano Med Invests โฌ250M in New Radiopharmaceutical Facility in France to Boost Cancer Therapy Production ๐

Orano Med is making a significant investment in Franceโs radiopharmaceutical sector with the construction of a โฌ250 million Advanced Thorium Extraction Facility (ATEF) in Bessines-sur-Gartempe. This 7,000-square-meter site will produce thorium-228, a key precursor for lead-212-based radioligand therapies, which are used in targeted cancer treatments.
๐๐ฒ๐ ๐๐ถ๐ด๐ต๐น๐ถ๐ด๐ต๐๐ ๐ผ๐ณ ๐๐ต๐ฒ ๐ฃ๐ฟ๐ผ๐ท๐ฒ๐ฐ๐:
- Expected opening: 2027
- Capacity: Will increase lead-212 extraction tenfold, ensuring supply for clinical trials and commercial treatments
- Production Goal: 100,000 radiopharmaceutical doses per year within the next decade
- Job Creation: 70 direct jobs + 100 indirect employment opportunities
- Government Support: โฌ22 million funding from the France 2030 program
This facility follows Orano Medโs recent expansion into the U.S., where it is building a radiopharma production plant in Brownsburg, Indiana (Alpha Therapy Laboratory - ATLab). Additionally, Orano Med has entered a โฌ300 million radioligand partnership with Sanofi, which includes Sanofi taking a 16% equity stake in the venture.
Genui and SHS Capital Invest in Germanyโs ROTOP to Strengthen Radiopharmaceuticals Industry ๐

ROTOP Pharmaka GmbH, a leading German manufacturer and CDMO specializing in radiopharmaceuticals, has secured a strategic investment from Genui and SHS Capital. This partnership is set to enhance ROTOPโs expertise in developing and producing innovative medical imaging and therapeutic solutions, reinforcing its role in the growing radiopharmaceutical market.
With this capital injection, ROTOP aims to expand its capabilities, drive innovation, and strengthen its market presence both in Germany and internationally. This investment highlights the increasing importance of radiopharmaceuticals in modern healthcare, particularly in diagnostics and targeted therapies.
Photo: rotop-pharmaka.de
Zimmer Biomet to Acquire Paragon 28 in $1.1 Billion Deal ๐ฐ

Medical device giant Zimmer Biomet has announced its acquisition of Paragon 28 for approximately $1.1 billion, aiming to expand its orthopedic surgical device portfolio. The deal will strengthen Zimmer Biometโs offerings in foot and ankle surgical implants, as well as its fracture, trauma, and joint replacement businesses.
Under the agreement, Zimmer Biomet will pay $13.00 per share in cash, an 8.3% premium on Paragonโs closing price. Additionally, shareholders may receive up to $1 per share based on performance milestones, potentially increasing the dealโs value to $1.2 billion.
Zimmer Biomet plans to finance the acquisition through a mix of cash and debt, with completion expected in the first half of 2025. While the company expects a short-term 3% dip in adjusted profits for 2025, the acquisition is positioned as a strategic long-term growth move.
Upcoming Pharma Surge in Germany: Sanofi's โฌ1.3 Billion Insulin Manufacturing Investment in Frankfurt ๐

Sanofi is considering a โฌ1.3โโฌ1.5 billion investment to upgrade its insulin manufacturing site in Frankfurt, choosing Germany over relocating production to France. This move comes amid a wave of pharmaceutical investments in Germany, including Daiichi Sankyo's โฌ1 billion cancer research facility near Munich and Eli Lilly's โฌ2.5 billion injectable drug site in Rhineland-Palatinate.
These projects reflect growing confidence in Germany's industrial and healthcare landscape despite economic challenges like inflation and rising living costs. Sanofiโs Q1 2024 sales surge of 6.7%, driven by products like Dupix